Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs

Next Previous
Search
Trial Profile

ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Cancer metastases; Carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTRACTION-03
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 13 Sep 2022 Results assessing survival heterogeneity and the underlying fraction of long-term survivorship in advanced esophageal squamous cell carcinoma, presented at the 47th European Society for Medical Oncology Congress.
    • 16 Mar 2022 Results published in the Clinical Cancer Research
    • 15 Nov 2021 Results (N=1683) of meta-analysis and systematic review evaluating the efficacy and safety of PD-1 inhibitors monotherapy versus chemotherapy in second-line treatment of AEC published in the Clinical Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top